Clinical Trial Update: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease [Phase 1]

View source ↗

Summary

Phase 1 study update for FT819 in B-cell–mediated autoimmune diseases; recruitment is ongoing for ANCA-associated vasculitis, idiopathic inflammatory myositis, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Idiopathic Inflammatory Myositis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• FT819

Snippet

Sponsor: Fate Therapeutics | Conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 | Status: RECRUITING